Wound Dressings - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the wound dressings market size is expected to grow from USD 5.22 billion in 2025 to USD 5.42 billion in 2026 and is forecast to reach USD 6.47 billion by 2031 at 3.62% CAGR over 2026-2031.

This report is Segmented by Type (Advanced Wound Dressings [Foams, Hydrocolloids, and More] and Traditional Wound Dressings [Bandages, and More]), Application (Surgical and Traumatic Wounds, Diabetic Foot Ulcers and More), End User (Hospitals and Surgical Centers, Specialty Wound Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Wound Dressings Market Trends and Insights

Rising Incidence of Chronic Wounds & Diabetic Ulcers

Global diabetes prevalence hit 828 million adults in 2022 and is projected to reach 1.31 billion by 2050, triggering an upsurge in chronic wounds that strain health-system capacity. Between 19% and 34% of people with diabetes develop foot ulcers over their lifetime, and up to 24% of those cases progress to amputation. Moisture-retentive hydrocolloids, antibacterial silver foams, and collagen matrices are increasingly adopted to accelerate granulation, but cost barriers persist in resource-limited regions. Multidisciplinary foot-care teams recommended by the American Diabetes Association have gained traction in OECD countries, yet clinician shortages and low health literacy impede replication elsewhere. As a result, diabetic ulcer management is emerging as the primary growth engine of the wound dressings market.

Escalating Volume of Surgical Procedures Worldwide

More than 300 million surgeries are performed each year, and surgical site infections continue to complicate up to 11% of cases in low-resource settings. High-risk procedures such as joint replacements and cardiac bypass increasingly rely on prophylactic single-use NPWT systems that reduce edema and bacterial contamination. Devices like Smith & Nephew's PICO and Solventum's Prevena earned FDA clearances in 2024-2025, underscoring regulatory confidence in miniaturized pump formats. Conversely, the majority of clean, low-risk wounds in emerging economies are still managed with gauze due to budget ceilings, sustaining dual-track product demand within the wound dressings market.

High Price-Premium Over Traditional Dressings

Advanced foams, hydrocolloids, and NPWT devices cost five to twenty times more than basic gauze, a differential that blocks uptake in publicly funded hospitals across Asia, Africa, and Latin America. The WHO Essential Medicines List continues to recommend gauze and bandages, reinforcing low-cost procurement preferences. Bulk purchasing contracts that bundle wound products with surgical supplies further steer budgets toward traditional dressings, fueling a growth rate that already exceeds the overall wound dressings market trajectory.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Shift Toward Moist-Active & NPWT-Integrated Dressings
2. Expanding Reimbursement for Home-Based Wound Care in OECD Nations
3. Limited Clinician & Patient Awareness in Emerging Economies

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Advanced dressings accounted for 65.55% of wound dressings market revenue in 2025, anchored by foam, hydrocolloid, and silver platforms widely used in chronic-wound clinics. Foams and hydrocolloids thrive on versatility, handling everything from pressure ulcers to post-surgical incisions. Antimicrobial formats harness silver, iodine, or PHMB, but tightening stewardship policies could soften growth. Smart sensor-enabled dressings remain in pilot phases pending FDA software validation, while alginate, collagen, and super-absorbent materials occupy niche positions addressing highly exudative or regenerating tissues.

Traditional dressings, despite lower value capture, are growing at 5.25% CAGR through 2031, well above the wound dressings market average, as governments in India, Nigeria, and Indonesia scale mass-procurement of gauze for primary-care and emergency stockpiles. Disaster relief protocols also favor gauze for scalability and shelf stability. The widening price gap sustains a dual-speed landscape: advanced innovations push clinical outcomes in high-income settings, while basic products retain primacy wherever cost ceilings prevail.

Geography Analysis

North America retains leadership with 45.13% share in 2025, propelled by Medicare coverage, high per-capita spending, and mature specialty-wound networks. The prevalence of diabetes, exceeding 37 million adults in the United States, together with 17.3% of the population aged 65+ in 2023, sustains a heavy chronic-wound caseload. Market growth in the region is moderated by value-based purchasing models that pressure suppliers to prove outcome parity at lower cost.

Europe posts the fastest regional CAGR at 4.51% to 2031, supported by 500-plus specialized wound centers in Germany, net-zero procurement mandates under the Greener NHS framework, and extensive home-care reimbursement in France and the Nordics. The continent's 65-plus cohort will reach nearly 30% by 2050, guaranteeing chronic-wound demand expansion. Regulatory heterogeneity across member states complicates portfolio rollouts yet offers scope for localization strategies.

Asia-Pacific, Middle East & Africa, and South America represent the steepest volume growth, led by rising surgical counts and the world's largest diabetes cohorts in China and India. Procurement remains dominated by traditional dressings, but tier-one urban hospitals are piloting NPWT and hydrocolloids, setting an adoption runway as purchasing power improves. Companies able to navigate divergent approval pathways and price thresholds stand to gain an incremental slice of the wound dressings market.

1. Advancis Medical
2. Argentum Medical
3. Axio Biosolutions
4. B. Braun
5. Baxter
6. Cardinal Health
7. Coloplast
8. Convatec
9. DermaRite Industries
10. DeRoyal Industries
11. Hollister
12. Integra LifeSciences
13. Johnson & Johnson
14. Lohmann & Rauscher
15. MediWound
16. Medline Industries
17. Medtronic
18. MiMedx Group
19. Molnlycke Health Care
20. Organogenesis
21. Hartmann Group
22. Smiths Group
23. Solventum Corporation
24. Urgo Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support